Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Accumulated Expenses (2023 - 2025)

Contineum Therapeutics (CTNM) has 3 years of Accumulated Expenses data on record, last reported at $2.8 million in Q3 2025.

  • For Q3 2025, Accumulated Expenses rose 29.26% year-over-year to $2.8 million; the TTM value through Sep 2025 reached $2.8 million, up 29.26%, while the annual FY2024 figure was $6.7 million, 252.47% up from the prior year.
  • Accumulated Expenses reached $2.8 million in Q3 2025 per CTNM's latest filing, down from $3.7 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $6.7 million in Q4 2024 and bottomed at $959000.0 in Q1 2024.
  • Average Accumulated Expenses over 3 years is $3.1 million, with a median of $2.7 million recorded in 2024.
  • The widest YoY moves for Accumulated Expenses: up 301.36% in 2025, down 29.26% in 2025.
  • A 3-year view of Accumulated Expenses shows it stood at $1.9 million in 2023, then surged by 252.47% to $6.7 million in 2024, then crashed by 58.07% to $2.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $2.8 million in Q3 2025, $3.7 million in Q2 2025, and $3.8 million in Q1 2025.